Cargando…
The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
OBJECTIVE: Oncologic treatment can affect the adrenal glands, which in stressful situations may lead to life threatening adrenal crisis. The aim of the study was to assess adrenal function in pediatric acute lymphoblastic leukemia (ALL) survivors and to identify the best markers for this assessment....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724047/ https://www.ncbi.nlm.nih.gov/pubmed/35633644 http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-2-2 |
_version_ | 1784844324621516800 |
---|---|
author | Hull, Barbara Wędrychowicz, Anna Ossowska, Magdalena Furtak, Aleksandra Badacz, Joanna Skoczeń, Szymon Starzyk, Jerzy B. |
author_facet | Hull, Barbara Wędrychowicz, Anna Ossowska, Magdalena Furtak, Aleksandra Badacz, Joanna Skoczeń, Szymon Starzyk, Jerzy B. |
author_sort | Hull, Barbara |
collection | PubMed |
description | OBJECTIVE: Oncologic treatment can affect the adrenal glands, which in stressful situations may lead to life threatening adrenal crisis. The aim of the study was to assess adrenal function in pediatric acute lymphoblastic leukemia (ALL) survivors and to identify the best markers for this assessment. METHODS: Forty-three ALL survivors, mean age 8.5±3.6 years and 45 age and sex-matched healthy controls were recruited to the study. ALL patients were assessed once within five years following oncological treatment completion. Fasting blood samples were collected from all participants to measure: fasting blood glucose (FBG); cortisol; aldosterone; plasma renin activity (PRA); dehydroepiandrostendione-sulfate (DHEA-S); and adrenocorticotropic hormone (ACTH). Moreover, diurnal profile of cortisol levels and 24-hour urinary free cortisol (UFC) were assessed. ALL survivors underwent a test with 1 ug of synthetic ACTH. RESULTS: The study revealed lower level of PRA (1.94±0.98 ng/mL/h vs 3.61±4.85 ng/mL/h, p=0.029) and higher FBG (4.6±0.38 mmol/L vs 4.41±0.39 mmol/L, p=0.018) in the ALL group compared to controls. UFC correlated with evening cortisol (p=0.015, r=0.26), midnight cortisol (p=0.002, r=0.33), and DHEA-S (p=0.004, r=0.32). UFC also correlated with systolic and diastolic blood pressure (p=0.033, r=0.23 and p=0.005, r=0.31, respectively). The ACTH test confirmed impaired adrenal function in 4/43 ALL survivors (9%). Two of the patients who needed permanent hydrocortisone replacement had low UFC, midnight cortisol and DHEA-S levels. CONCLUSION: These results highlight the importance of reviewing adrenal gland functionality after chemo/radiotherapy in ALL survivors. DHEA-S proved to be a good marker to assess the adrenal glands after oncological therapy. Post-treatment disturbances of the adrenal axis could be associated with metabolic complications. |
format | Online Article Text |
id | pubmed-9724047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-97240472022-12-12 The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia Hull, Barbara Wędrychowicz, Anna Ossowska, Magdalena Furtak, Aleksandra Badacz, Joanna Skoczeń, Szymon Starzyk, Jerzy B. J Clin Res Pediatr Endocrinol Original Article OBJECTIVE: Oncologic treatment can affect the adrenal glands, which in stressful situations may lead to life threatening adrenal crisis. The aim of the study was to assess adrenal function in pediatric acute lymphoblastic leukemia (ALL) survivors and to identify the best markers for this assessment. METHODS: Forty-three ALL survivors, mean age 8.5±3.6 years and 45 age and sex-matched healthy controls were recruited to the study. ALL patients were assessed once within five years following oncological treatment completion. Fasting blood samples were collected from all participants to measure: fasting blood glucose (FBG); cortisol; aldosterone; plasma renin activity (PRA); dehydroepiandrostendione-sulfate (DHEA-S); and adrenocorticotropic hormone (ACTH). Moreover, diurnal profile of cortisol levels and 24-hour urinary free cortisol (UFC) were assessed. ALL survivors underwent a test with 1 ug of synthetic ACTH. RESULTS: The study revealed lower level of PRA (1.94±0.98 ng/mL/h vs 3.61±4.85 ng/mL/h, p=0.029) and higher FBG (4.6±0.38 mmol/L vs 4.41±0.39 mmol/L, p=0.018) in the ALL group compared to controls. UFC correlated with evening cortisol (p=0.015, r=0.26), midnight cortisol (p=0.002, r=0.33), and DHEA-S (p=0.004, r=0.32). UFC also correlated with systolic and diastolic blood pressure (p=0.033, r=0.23 and p=0.005, r=0.31, respectively). The ACTH test confirmed impaired adrenal function in 4/43 ALL survivors (9%). Two of the patients who needed permanent hydrocortisone replacement had low UFC, midnight cortisol and DHEA-S levels. CONCLUSION: These results highlight the importance of reviewing adrenal gland functionality after chemo/radiotherapy in ALL survivors. DHEA-S proved to be a good marker to assess the adrenal glands after oncological therapy. Post-treatment disturbances of the adrenal axis could be associated with metabolic complications. Galenos Publishing 2022-12 2022-12-01 /pmc/articles/PMC9724047/ /pubmed/35633644 http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-2-2 Text en ©Copyright 2022 by Turkish Pediatric Endocrinology and Diabetes Society | The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Hull, Barbara Wędrychowicz, Anna Ossowska, Magdalena Furtak, Aleksandra Badacz, Joanna Skoczeń, Szymon Starzyk, Jerzy B. The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia |
title | The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia |
title_full | The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia |
title_fullStr | The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia |
title_full_unstemmed | The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia |
title_short | The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia |
title_sort | assessment of the hypothalamic-pituitary-adrenal axis after oncological treatment in pediatric patients with acute lymphoblastic leukemia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724047/ https://www.ncbi.nlm.nih.gov/pubmed/35633644 http://dx.doi.org/10.4274/jcrpe.galenos.2022.2022-2-2 |
work_keys_str_mv | AT hullbarbara theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT wedrychowiczanna theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT ossowskamagdalena theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT furtakaleksandra theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT badaczjoanna theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT skoczenszymon theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT starzykjerzyb theassessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT hullbarbara assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT wedrychowiczanna assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT ossowskamagdalena assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT furtakaleksandra assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT badaczjoanna assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT skoczenszymon assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia AT starzykjerzyb assessmentofthehypothalamicpituitaryadrenalaxisafteroncologicaltreatmentinpediatricpatientswithacutelymphoblasticleukemia |